WL Gore & Associates Inc. expects US FDA approval of its Tigris heparin-coated peripheral vascular stent, announced Aug. 2, to expand the peripheral artery disease patient population that can be safely treated with vascular stents.
According to Gore, there are between 8 million and 12 million peripheral artery disease patients in the US. Treating diseased vessels in the leg, especially behind the knee, is especially difficult, because the stent is subject to extension, flexion, torsion and compression as the patient bends their knee, often causing stents implanted in these arteries to fracture
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?